Revolutionary CAR-T therapy targets solid tumors, shows promise

Summary: CAR-T cell therapy has transformed blood cancer treatment in the last decade. A new study by Dr. Xingxing Zang introduces TOP CAR, a more potent version targeting solid tumors. In animal trials, TOP CAR showed improved survival rates compared to existing CAR-T therapies. Zang's innovative approach includes a new co-stimulator, TMIGD2, yielding promising results. This advancement could lead to clinical trials for solid tumors resistant to current treatments.

Full article